tetano
Editor, Senior Moderator
J Clin Med
. 2021 Dec 11;10(24):5799.
doi: 10.3390/jcm10245799.
Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic?
Diego Fernández-Lázaro[SUP] 1 2 [/SUP], Nerea Sánchez-Serrano[SUP] 3 [/SUP], Juan Mielgo-Ayuso[SUP] 4 [/SUP], Juan Luis García-Hernández[SUP] 5 6 [/SUP], Jerónimo J González-Bernal[SUP] 4 [/SUP], Jesús Seco-Calvo[SUP] 7 8 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a multisystem illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which can manifest with a multitude of symptoms in the setting of end-organ damage, though it is predominantly respiratory. However, various symptoms may remain after acute SARS-CoV-2 infection, and this condition is referred to as "Long COVID" (LC). Patients with LC may develop multi-organ symptom complex that remains 4-12 weeks after the acute phase of illness, with symptoms intermittently persisting over time. The main symptoms are fatigue, post-exertional malaise, cognitive dysfunction, and limitation of functional capacity. Pediatric patients developed the main symptoms of LC like those described in adults, although there may be variable presentations of LC in children. The underlying mechanisms of LC are not clearly known, although they may involve pathophysiological changes generated by virus persistence, immunological alterations secondary to virus-host interaction, tissue damage of inflammatory origin and hyperactivation of coagulation. Risk factors for developing LC would be female sex, more than five early symptoms, early dyspnea, previous psychiatric disorders, and alterations in immunological, inflammatory and coagulation parameters. There is currently no specific treatment for LC, but it could include pharmacological treatments to treat symptoms, supplements to restore nutritional, metabolic, and gut flora balance, and functional treatments for the most disabling symptoms. In summary, this study aims to show the scientific community the current knowledge of LC.
Keywords: SARS-CoV-2; biomarkers; long COVID; pathways; symptomatology; therapy.
. 2021 Dec 11;10(24):5799.
doi: 10.3390/jcm10245799.
Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic?
Diego Fernández-Lázaro[SUP] 1 2 [/SUP], Nerea Sánchez-Serrano[SUP] 3 [/SUP], Juan Mielgo-Ayuso[SUP] 4 [/SUP], Juan Luis García-Hernández[SUP] 5 6 [/SUP], Jerónimo J González-Bernal[SUP] 4 [/SUP], Jesús Seco-Calvo[SUP] 7 8 [/SUP]
Affiliations
- PMID: 34945095
- DOI: 10.3390/jcm10245799
Abstract
Coronavirus disease 2019 (COVID-19) is a multisystem illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which can manifest with a multitude of symptoms in the setting of end-organ damage, though it is predominantly respiratory. However, various symptoms may remain after acute SARS-CoV-2 infection, and this condition is referred to as "Long COVID" (LC). Patients with LC may develop multi-organ symptom complex that remains 4-12 weeks after the acute phase of illness, with symptoms intermittently persisting over time. The main symptoms are fatigue, post-exertional malaise, cognitive dysfunction, and limitation of functional capacity. Pediatric patients developed the main symptoms of LC like those described in adults, although there may be variable presentations of LC in children. The underlying mechanisms of LC are not clearly known, although they may involve pathophysiological changes generated by virus persistence, immunological alterations secondary to virus-host interaction, tissue damage of inflammatory origin and hyperactivation of coagulation. Risk factors for developing LC would be female sex, more than five early symptoms, early dyspnea, previous psychiatric disorders, and alterations in immunological, inflammatory and coagulation parameters. There is currently no specific treatment for LC, but it could include pharmacological treatments to treat symptoms, supplements to restore nutritional, metabolic, and gut flora balance, and functional treatments for the most disabling symptoms. In summary, this study aims to show the scientific community the current knowledge of LC.
Keywords: SARS-CoV-2; biomarkers; long COVID; pathways; symptomatology; therapy.